Dr. Reddy's Laboratories Ltd (RDY) Revenue-to-Profit Sankey Flow & SEC XBRL Financials
Dr. Reddy's Laboratories Ltd (RDY) carries a Roarable Rating of C (Hold) with 65/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
How RDY Turns Every Dollar of Sales Into Real Bottom-Line Profit
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring RDY)
- ✓Live walkthrough of RDY's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
RDY Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on RDY today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for RDY. Explore sector supply chains on /butterfly.
RDY Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDHow profitable is Dr. Reddy's Laboratories Ltd (RDY)?
In Trailing 12 Months, RDY converted $4.0B of revenue into a 41% gross margin, 13.9% operating margin, and $260.3M in free cash flow (6.5% FCF margin).